The first phase 3 trials are due to start in the first half of next year, using devices manufactured at GSK’s facility in Evreux, France. “If successful, this could lead to regulatory ...

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Kering, GSK and Holcim are adopting science-based targets aimed at protecting land and water globally.

European stocks closed broadly higher on Tuesday with investors largely making cautious moves, digesting mixed earnings updates and ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

GSK’s NgG shot is based on generalised modules ... approximately 750 healthy adult subjects in the US, the UK, France, Germany, Spain, Brazil, the Philippines, and South Africa, with a readout ...